Wedbush cut its price target for Rocket Pharmaceuticals from $15 to $12 after the company's third-quarter results.

Nov 13, 2026, 9:24 AM ETOpinionRead the original at marketscreener.com

Neutral

Wedbush lowered its share target but kept its Outperform rating. The story gives no new company results, so these mixed views do not clearly change Rocket's outlook.

RCKT · Rocket Pharmaceuticals

AI read · Neutral

The AI's read

This is an analyst's view, not a new company result. The lower target points in a negative direction, but keeping Outperform points the other way. The story gives no quarter details to settle the difference.

Get alerts for RCKT

Follow Rocket Pharmaceuticals (RCKT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RCKT

Free on the App Store and Google Play, or on the web.